Ecotest COVID-19 IgG/IgM Rapid Test Devices
Current Inventory has long expiration date of March 2024!
(20 Tests per Kit)
Includes 20 droppers, 20 alcohol wipes, 20 lancets, 1 buffer, 1 insert, and 1 procedure card - FDA EUA Authorized and CLIA waived.
For COVID-19 IgG/IgM controls, click here: AZ-COVID-19 CTRL
Features and Benefits
- First ever FDA EUA authorized CLIA waived finger stick whole blood IGM/IGG combination antibody test.
- Results in 15 minutes.
- Each kit contains 20 test devices and everything you need to complete the test including lancets, droppers, buffer, and alcohol wipes.
All EUA authorized COVID-19 products are non-returnable with no exceptions unless damaged in transit, product is recalled for manufacturer erformacne issues or deemed defective by the manufacturer. Buyer should beware that EUA authorized products could be revoked by FDA and removed from authorization list. Products that are revoked are non-returnable and non-refundable. Note: Manufacturer recalls are returnable for replacement product only. No Cash refund will be given for manufacturer-initiated recall.
* REQUIRED FIELDS IN ORDER TO PURCHASE
- Immunoassay for infectious agent antibody(ies), qualitative or semi quantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
Current Procedural Terminology (CPT®) code 86328 was adopted by the American Medical Association (AMA) CPT® Editorial Panel on April 10, 2020 and is effective for use immediately on or after that date. The code was established to report antibody testing performed using a single-step method immunoassay and will allow for tracking of COVID-19 antibody testing. The test is performed using a strip that contains all of the critical components for testing from a blood or serum sample. According to the AMA, 86328 should be reported once for each reagent strip assay. If a single strip tests for multiple antibody classes, only one unit of service should be reported. There is currently no reimbursement information available for this code, but it should be available with no cost-sharing for Medicare beneficiaries using modifier CS, Cost-sharing for specified COVID-19 testing-related services that result in an order for or administration of a COVID-19 test. Payers other than Medicare may have different policies, so it will be important to contact them regarding their specific policies.